Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett Sells 4,902 Shares

Insmed Incorporated (NASDAQ:INSM) COO Roger Adsett sold 4,902 shares of Insmed stock in a transaction on Friday, January 10th. The shares were sold at an average price of $63.68, for a total value of $312,159.36. Following the transaction, the chief operating officer now owns 147,539 shares in the company, valued at $9,395,283.52. This trade represents a 3.22 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Roger Adsett also recently made the following trade(s):

• On Tuesday, January 7th, Roger Adsett sold 2,444 shares of Insmed stock. The stock was sold at an average price of $65.95, for a total value of $161,181.80.

Insmed Price Performance

Shares of INSM stock traded down $0.47 on Friday, reaching $65.25. The company’s stock had a trading volume of 3,087,759 shares, compared to its average volume of 1,881,810. The stock’s fifty day simple moving average is $71.29 and its 200-day simple moving average is $72.44. Insmed Incorporated has a 1 year low of $21.92 and a 1 year high of $80.53. The company has a market capitalization of $11.67 billion, a price-to-earnings ratio of -11.76 and a beta of 1.12. The company has a current ratio of 6.37, a quick ratio of 5.99 and a debt-to-equity ratio of 2.03.

Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, October 31st. The biopharmaceutical company reported ($1.27) EPS for the quarter, missing analysts’ consensus estimates of ($1.19) by ($0.08). The business had revenue of $93.40 million for the quarter, compared to analyst estimates of $93.36 million. The firm’s quarterly revenue was up 18.1% on a year-over-year basis. During the same period in the prior year, the firm earned ($1.10) earnings per share. Analysts forecast that Insmed Incorporated will post -5.44 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently issued reports on the stock. Bank of America increased their target price on shares of Insmed from $84.00 to $86.00 and gave the stock a “buy” rating in a report on Wednesday, October 9th. Truist Financial reissued a “buy” rating and issued a $105.00 price objective (up from $100.00) on shares of Insmed in a research note on Friday, November 1st. JPMorgan Chase & Co. lifted their target price on shares of Insmed from $74.00 to $83.00 and gave the company an “overweight” rating in a research note on Friday, November 22nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $90.00 price target on shares of Insmed in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating and sixteen have given a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $83.67.

Institutional Investors Weigh In On Insmed

Several institutional investors have recently modified their holdings of INSM. CIBC Asset Management Inc increased its position in shares of Insmed by 3.5% during the 3rd quarter. CIBC Asset Management Inc now owns 4,438 shares of the biopharmaceutical company’s stock valued at $324,000 after purchasing an additional 149 shares during the last quarter. Commerce Bank boosted its stake in Insmed by 2.4% during the third quarter. Commerce Bank now owns 6,833 shares of the biopharmaceutical company’s stock worth $499,000 after buying an additional 163 shares during the period. GAMMA Investing LLC increased its position in Insmed by 71.3% during the third quarter. GAMMA Investing LLC now owns 538 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 224 shares during the last quarter. Atomi Financial Group Inc. raised its stake in shares of Insmed by 1.4% in the third quarter. Atomi Financial Group Inc. now owns 23,248 shares of the biopharmaceutical company’s stock valued at $1,697,000 after acquiring an additional 314 shares during the period. Finally, V Square Quantitative Management LLC purchased a new stake in shares of Insmed in the third quarter valued at $30,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.